Humacyte, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Humacyte, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-58.4×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 75% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
1/3 · 1/3Sales grew in 1 of the last 3 years; profit grew in 1 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-43.3×Operating cash was negative last year, while some debt falls due within a year.
Lower than 70% of Healthcare companies in United States.
Cash Cushion Ratio
−13%Debt, after subtracting cash, equals 13% of its market value (net debt).
Lower than 80% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
Humacyte, Inc. made a loss over the last year. Humacyte, Inc. owes $0.77 for every $1 it owns. Humacyte, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossHumacyte, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
3.67The share price is 3.67 times Humacyte, Inc.'s book value per share, higher than 62% of Healthcare companies in United States.
Market cap
$115 MThe total market value of all of Humacyte, Inc.'s shares at today's price (share price × number of shares), smaller than 64% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$31 MWhat Humacyte, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.11Net worth divided by the number of shares. The share price of $0.41 is 3.7 times this, which is the P/B above.
Return on equity (ROE)
-547.9%Humacyte, Inc. lost 547.9% of its shareholders' money over the last year, lower than 94% of Healthcare companies in United States.
Owes vs Owns
0.77×Humacyte, Inc. owes $0.77 for every $1 it owns (moderate), higher than 76% of Healthcare companies in United States.
Dividend yield
NoneHumacyte, Inc. does not currently pay a dividend.
Profit growth
LossHumacyte, Inc. made a loss in each of the last two years.
Profit margin
-2003.6%Humacyte, Inc. lost $2004 for every $100 of revenue.
Interest cover
Not coveredHumacyte, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net debtHumacyte, Inc. had $14 M more debt than cash (net debt) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Humacyte, Inc.: $115 M ÷ $31 M (30 Jun 2026) = 3.7.
What is Humacyte, Inc.'s return on equity?
Humacyte, Inc. lost 547.9% of its shareholders' money over the last year, lower than 94% of Healthcare companies in United States.
How much does Humacyte, Inc. owe compared with what it owns?
Humacyte, Inc. owes $0.77 for every $1 it owns (moderate), higher than 76% of Healthcare companies in United States.
Does Humacyte, Inc. pay a dividend?
No. Humacyte, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.